Bioinformatics Analysis of Hub Genes and Potential Therapeutic Agents Associated with Gastric Cancer

References

• Arai HN, Akajima TE. Recent developments of systemic chemotherapy for gastric cancer. Cancers (Basel). 2020;12(5):1100. doi:10.3390/cancers12051100
   PubMed Web of Science ®Google Scholar
• Magnelli L, Schiavone N, Staderini F, et al. MAP kinases pathways in gastric cancer. Int J Mol Sci. 2020;21:2893. doi:10.3390/ijms21082893
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Rafiei H, Mohammadinejad R, et al. Wnt-regulating microRNAs role in gastric cancer malignancy. Life Sci. 2020;250:117547. doi:10.1016/j.lfs.2020.11754732173311
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Orouei S, et al. STAT3 pathway in gastric cancer: signaling, therapeutic targeting and future prospects. Biology (Basel). 2020;9. doi:10.3390/biology9060126
   PubMed Web of Science ®Google Scholar
• Kumar V, Soni P, Garg M, et al. Emerging therapies in the management of advanced-stage gastric cancer. Front Pharmacol. 2018;9:404. doi:10.3389/fphar.2018.0040430271341
   PubMed Web of Science ®Google Scholar
• Oh SC, Sohn BH, Cheong JH, et al. Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018;9:1777. doi:10.1038/s41467-018-04179-829725014
   PubMed Web of Science ®Google Scholar
• Meng LB, Shan MJ, Qiu Y, et al. TPM2 as a potential predictive biomarker for atherosclerosis. Aging (Albany NY). 2019;11:6960–6982. doi:10.18632/aging.10223131487691
   PubMedGoogle Scholar
• Sun CC, Zhou Q, Hu W, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018;10:973–987. doi:10.18632/aging.10144129754146
   PubMedGoogle Scholar
• Pfeifer SP. From next-generation resequencing reads to a high-quality variant data set. Heredity. 2017;118:111–124. doi:10.1038/hdy.2016.10227759079
   PubMed Web of Science ®Google Scholar
• Owzar K, Barry WT, Jung SH, et al. Statistical challenges in preprocessing in microarray experiments in cancer. Clin Cancer Res. 2008;14:5959–5966. doi:10.1158/1078-0432.CCR-07-453218829474
   PubMed Web of Science ®Google Scholar
• Huber W, Carey VJ, Gentleman R, et al. Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods. 2015;12:115–121. doi:10.1038/nmeth.325225633503
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47–e47. doi:10.1093/nar/gkv00725605792
   PubMed Web of Science ®Google Scholar
• Ginestet C. ggplot2: elegant graphics for data analysis. J R Stat Soc A Stat. 2011;174:245. doi:10.1111/j.1467-985X.2010.00676_9.x
   Web of Science ®Google Scholar
• Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14:26–38. doi:10.5114/pg.2018.8000130944675
   PubMed Web of Science ®Google Scholar
• Gilkes DM, Semenza GL, Wirtz D. Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer. 2014;14:430–439. doi:10.1038/nrc372624827502
   PubMed Web of Science ®Google Scholar
• Climent M, Pera M, Aymar I, et al. Bone health in long-term gastric cancer survivors: a prospective study of high-dose vitamin D supplementation using an easy administration scheme. J Bone Miner Metab. 2018;36:462–469. doi:10.1007/s00774-017-0856-128766134
   PubMed Web of Science ®Google Scholar
• Jang M, Koh I, Lee SJ, et al. Droplet-based microtumor model to assess cell-ECM interactions and drug resistance of gastric cancer cells. Sci Rep. 2017;7:41541. doi:10.1038/srep4154128128310
   PubMed Web of Science ®Google Scholar
• Liu X, Chu KM. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. 2014;2014:637308. doi:10.1155/2014/63730825184143
   PubMed Web of Science ®Google Scholar
• Zhou ZH, Ji CD, Xiao HL, et al. Reorganized collagen in the tumor microenvironment of gastric cancer and its association with prognosis. J Cancer. 2017;8:1466–1476. doi:10.7150/jca.1846628638462
   PubMed Web of Science ®Google Scholar
• Giussani M, Triulzi T, Sozzi G, et al. Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. Cells. 2019;8:81. doi:10.3390/cells8020081
   PubMed Web of Science ®Google Scholar
• Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243–1253. doi:10.15252/embr.20143924625381661
   PubMed Web of Science ®Google Scholar
• Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36:171–198. doi:10.1007/s10585-019-09966-130972526
   PubMed Web of Science ®Google Scholar
• Poltavets V, Kochetkova M, Pitson SM, et al. The role of the extracellular matrix and its molecular and cellular regulators in cancer cell plasticity. Front Oncol. 2018;8:431. doi:10.3389/fonc.2018.0043130356678
   PubMed Web of Science ®Google Scholar
• Malik R, Lelkes PI, Cukierman E. Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 2015;33:230–236. doi:10.1016/j.tibtech.2015.01.00425708906
   PubMed Web of Science ®Google Scholar
• Morrissey MA, Jayadev R, Miley GR, et al. SPARC promotes cell invasion in vivo by decreasing type IV collagen levels in the basement membrane. PLoS Genet. 2016;12:e1005905. doi:10.1371/journal.pgen.100590526926673
   PubMed Web of Science ®Google Scholar
• Inoue M, Senju S, Hirata S, et al. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer. 2010;127:1393–1403. doi:10.1002/ijc.2516020063317
   PubMed Web of Science ®Google Scholar
• Mo A, Yang SW, Jiang YX, et al. Role of secreted protein acidic in hematogenous metastasis of gastric cancer. Eur Rev Med Pharmacol Sci. 2017;21:4311–4321.29077165
   PubMed Web of Science ®Google Scholar
• Cai X, Liu C, Zhang TN, et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J Cell Biochem. 2018;119:4717–4728. doi:10.1002/jcb.2665129274284
   PubMed Web of Science ®Google Scholar
• Wang J, Deng L, Huang J, et al. High expression of Fibronectin 1 suppresses apoptosis through the NF-kappaB pathway and is associated with migration in nasopharyngeal carcinoma. Am J Transl Res. 2017;9:4502–4511.29118912
   PubMed Web of Science ®Google Scholar
• Yang X, Hu Q, Hu LX, et al. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Discov Med. 2017;24:75–85.28972876
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang L, Wu S, et al. Bioinformatics analyses of the role of vascular endothelial growth factor in patients with non-small cell lung cancer. PLoS One. 2015;10:e0139285. doi:10.1371/journal.pone.013928526422603
   PubMed Web of Science ®Google Scholar
• Hong BB, Chen SQ, Qi YL, et al. Association of THBS1 rs1478605 T>C in 5ʹ-untranslated regions with the development and progression of gastric cancer. Biomed Rep. 2015;3:207–214. doi:10.3892/br.2015.41426075074
   PubMedGoogle Scholar
• Lin XD, Chen SQ, Qi YL, et al. Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol. 2012;106:94–100. doi:10.1002/jso.2303722231149
   PubMed Web of Science ®Google Scholar
• Tian Q, Liu Y, Zhang Y, et al. THBS2 is a biomarker for AJCC stages and a strong prognostic indicator in colorectal cancer. J BUON. 2018;23:1331–1336.30570855
   PubMed Web of Science ®Google Scholar
• Peng HY, Chang MC, Hu CM, et al. Thrombospondin-2 is a highly specific diagnostic marker and is associated with prognosis in pancreatic cancer. Ann Surg Oncol. 2019;26:807–814. doi:10.1245/s10434-018-07109-630569296
   PubMed Web of Science ®Google Scholar
• Kim H, Watkinson J, Varadan V, et al. Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genomics. 2010;3:51. doi:10.1186/1755-8794-3-5121047417
   PubMed Web of Science ®Google Scholar
• Andrlová H, Mastroianni J, Madl J, et al. Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin-β1 expression. Oncotarget. 2017;8:42901–42916. doi:10.18632/oncotarget.1716028476030
   PubMedGoogle Scholar
• Liu Y, Li W, Li X, et al. Expression and significance of biglycan in endometrial cancer. Arch Gynecol Obstet. 2014;289:649–655. doi:10.1007/s00404-013-3017-324013431
   PubMed Web of Science ®Google Scholar
• Jacobsen F, Kraft J, Schroeder C, et al. Up-regulation of Biglycan is associated with poor prognosis and PTEN deletion in patients with prostate cancer. Neoplasia (New York, N Y). 2017;19:707–715. doi:10.1016/j.neo.2017.06.003
   PubMed Web of Science ®Google Scholar
• Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014;15:786–801. doi:10.1038/nrm390425415508
   PubMed Web of Science ®Google Scholar
• Rong L, Huang W, Tian S, et al. COL1A2 is a novel biomarker to improve clinical prediction in human gastric cancer: integrating bioinformatics and meta-analysis. Pathol Oncol Res. 2018;24:129–134. doi:10.1007/s12253-017-0223-528401451
   PubMed Web of Science ®Google Scholar
• Oue N, Hamai Y, Mitani Y, et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res. 2004;64:2397–2405. doi:10.1158/0008-5472.CAN-03-351415059891
   PubMed Web of Science ®Google Scholar
• Uddin MN, Li M, Wang X. Identification of transcriptional markers and microRNA-mRNA regulatory networks in colon cancer by integrative analysis of mRNA and microRNA expression profiles in colon tumor stroma. Cells. 2019;8:1054. doi:10.3390/cells8091054
   PubMed Web of Science ®Google Scholar
• Gao YF, Mao XY, Zhu T, et al. COL3A1 and SNAP91: novel glioblastoma markers with diagnostic and prognostic value. Oncotarget. 2016;7:70494–70503. doi:10.18632/oncotarget.1203827655637
   PubMedGoogle Scholar
• Liu X, Wu J, Zhang D, et al. Identification of potential key genes associated with the pathogenesis and prognosis of gastric cancer based on integrated bioinformatics analysis. Front Genet. 2018;9:265. doi:10.3389/fgene.2018.0026530065754
   PubMed Web of Science ®Google Scholar
• Chai F, Liang Y, Zhang F, et al. Systematically identify key genes in inflammatory and non-inflammatory breast cancer. Gene. 2016;575:600–614. doi:10.1016/j.gene.2015.09.02526403314
   PubMed Web of Science ®Google Scholar
• Liu W, Wei H, Gao Z, et al. COL5A1 may contribute the metastasis of lung adenocarcinoma. Gene. 2018;665:57–66. doi:10.1016/j.gene.2018.04.06629702185
   PubMed Web of Science ®Google Scholar
• Li G, Li X, Yang M, et al. Prediction of biomarkers of oral squamous cell carcinoma using microarray technology. Sci Rep. 2017;7:42105. doi:10.1038/srep4210528176846
   PubMed Web of Science ®Google Scholar
• Zhao X, Cai H, Wang X, et al. Discovery of signature genes in gastric cancer associated with prognosis. Neoplasma. 2016;63:239–245. doi:10.4149/209_150531N30326774142
   PubMed Web of Science ®Google Scholar
• Désert R, Mebarki S, Desille M, et al. “Fibrous nests” in human hepatocellular carcinoma express a Wnt-induced gene signature associated with poor clinical outcome. Int J Biochem Cell Biol. 2016;81:195–207. doi:10.1016/j.biocel.2016.08.01727545991
   PubMed Web of Science ®Google Scholar
• Salem O, Erdem N, Jung J, et al. The highly expressed 5ʹisomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. BMC Genomics. 2016;17:566. doi:10.1186/s12864-016-2869-x27502506
   PubMed Web of Science ®Google Scholar
• Carnemolla B, Borsi L, Balza E, et al. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood. 2002;99:1659–1665. doi:10.1182/blood.V99.5.165911861281
   PubMed Web of Science ®Google Scholar
• Weide B, Eigentler T, Catania C, et al. A Phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunol Immunother. 2019;68:1547–1559. doi:10.1007/s00262-019-02383-z31482307
   PubMed Web of Science ®Google Scholar
• Sauer S, Erba PA, Petrini M, et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265–2274. doi:10.1182/blood-2008-06-16041619131554
   PubMed Web of Science ®Google Scholar
• Menssen HD, Harnack U, Erben U, et al. Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model. J Cancer Res Clin Oncol. 2018;144:499–507. doi:10.1007/s00432-017-2564-629327244
   PubMed Web of Science ®Google Scholar
• Chung JY, Ko JH, Lee YJ, et al. Surfactant-free solubilization and systemic delivery of anti-cancer drug using low molecular weight methylcellulose. J Control Release. 2018;276:42–49. doi:10.1016/j.jconrel.2018.02.02829476882
   PubMed Web of Science ®Google Scholar
• Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017. doi:10.1016/j.ctrv.2020.10201732335505
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23:3502–3508. doi:10.1200/JCO.2005.10.01715908660
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. doi:10.1056/NEJMoa06188417167137
   PubMed Web of Science ®Google Scholar
• Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144–2150. doi:10.1200/JCO.2009.26.784920368553
   PubMed Web of Science ®Google Scholar
• Kawamata H, Omotehara F, Nakashiro K, et al. Vesnarinone: a differentiation-inducing anti-cancer drug. Anticancer Drugs. 2003;14:391–395. doi:10.1097/00001813-200307000-0000112853878
   PubMed Web of Science ®Google Scholar
• Greenaway J, Henkin J, Lawler J, et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. Mol Cancer Ther. 2009;8:64–74. doi:10.1158/1535-7163.MCT-08-086419139114
   PubMed Web of Science ®Google Scholar